TY - JOUR
T1 - RNA aptamers targeting cancer stem cell marker CD133
AU - Shigdar, S.
AU - Qiao, L.
AU - Zhou, S.-F.
AU - Xiang, D.
AU - Wang, T.
AU - Li, Y.
AU - Lim, L.Y.
AU - Kong, L.
AU - Li, L.
AU - Duan, W.
PY - 2013
Y1 - 2013
N2 - The monoclonal antibody against the AC133 epitope of CD133 has been widely used as a cell surface marker of cancer stem cells in several different cancer types. Here, we describe the isolation and characterisation of two RNA aptamers, including the smallest described 15 nucleotide RNA aptamer, which specifically recognise the AC133 epitope and the CD133 protein with high sensitivity. As well, both these aptamers show superior tumour penetration and retention when compared to the AC133 antibody in a 3-D tumour sphere model. These novel CD133 aptamers will aid future development of cancer stem cell targeted therapeutics and molecular imaging. © 2012.
AB - The monoclonal antibody against the AC133 epitope of CD133 has been widely used as a cell surface marker of cancer stem cells in several different cancer types. Here, we describe the isolation and characterisation of two RNA aptamers, including the smallest described 15 nucleotide RNA aptamer, which specifically recognise the AC133 epitope and the CD133 protein with high sensitivity. As well, both these aptamers show superior tumour penetration and retention when compared to the AC133 antibody in a 3-D tumour sphere model. These novel CD133 aptamers will aid future development of cancer stem cell targeted therapeutics and molecular imaging. © 2012.
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84872847383&partnerID=MN8TOARS
U2 - 10.1016/j.canlet.2012.11.032
DO - 10.1016/j.canlet.2012.11.032
M3 - Article
C2 - 23196060
SN - 0304-3835
VL - 330
SP - 84
EP - 95
JO - Cancer Letters
JF - Cancer Letters
IS - 1
ER -
